法伯氏病 – Medxy AI

Predicting Cardiovascular Outcomes in Fabry Disease: Identifying High-Risk Markers in the Modern Therapeutic Era

By MedXY 03/02/2026

A multicenter study of 680 Fabry disease patients reveals that age, renal function, QRS duration, and left ventricular mass are critical independent predictors of major adverse cardiovascular events, highlighting persistent unmet needs despite available disease-specific therapies.

Cardiology news Radiology

Normal T1 Mapping Values Rule Out Adverse Cardiovascular Events in Fabry Cardiomyopathy: A New Multimodal Prognostic Score

By MedXY 01/05/2026

A prospective study of 167 Fabry disease patients identifies low T1 values, left ventricular hypertrophy, and late gadolinium enhancement as key predictors of major adverse cardiac events, leading to a robust new 3-year clinical prognostic score.

Cardiology Nephrology news

A New Frontier in Fabry Cardiomyopathy: Validating a T1-Inclusive Prognostic Score for Cardiovascular Risk

By MedXY 01/05/2026

This article explores a novel 3-year prognostic score for Fabry Disease cardiomyopathy, integrating CMR-derived T1 values, LV mass, and LGE extent to predict adverse events, emphasizing the negative predictive value of normal T1 mapping.